Matinas BioPharma Holdings MTNB
NYSE MTNB
$1.59 -0.11 (-6.48%)
As of: Oct 21, 2026 · 3:59 PM EDT

Matinas BioPharma Holdings (MTNB) Receivables (2018 - 2021)

Updated

Matinas BioPharma Holdings (MTNB) recorded Receivables of $980,000 in Q3 2021.

Analysis

Matinas BioPharma Holdings (MTNB) Receivables (2018 - 2021) Analysis & Trends

  • The Q3 2021 figure is the lowest quarterly Receivables since Q2 2018.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Receivables (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn 23.48 Bn
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn 19.05 Bn
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn 13.82 Bn
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn 12.56 Bn
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn 9.64 Bn
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn 15.68 Bn
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn 10.23 Bn
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn 5.06 Bn
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn 12.49 Bn
10 Matinas BioPharma Holdings 679,055.62 -11.91 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2021 980,000.00
Jun 30, 2018 89,813.00
API Access

Matinas BioPharma Holdings Receivables API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=receivables&ticker=MTNB&period=max&api_key=YOUR_API_KEY